Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53

A Second Controversial Duchenne Approval For Company

Executive Summary

The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.

You may also be interested in...



The 2010s: A Decade Of Acceleration, Innovation And Controversy

A look back at some of the defining events and trends in pharma over the past 10 years.

Finance Watch: Forma Raises $100m In Quest To Become A Sickle Cell Leader

The firm reorganized to focus on hemoglobinopathies and cancers after Celgene ended a multi-drug partnership. Also, Flagship funds a gene therapy start-up and brings in a business development veteran, Ultragenyx raises $320m in a royalty deal and Paratek secures up to $285m from BARDA. 

Lilly To Bring Forward Alzheimer’s Readout

After years of failure, expectations of solanezumab are very low – but Lilly still hoping for a signal. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141344

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel